Company Overview
Snapshot
Founded in April 2020 by Prof. Yaniv Erlich and Prof. Greg Hannon, Eleven Therapeutics operates with 11–50 employees. The company has raised $25.9M across three funding rounds from three investors. In August 2022, Eleven Therapeutics secured $22M in seed funding.
Business overview
Eleven Therapeutics is a startup focused on advancing mRNA therapeutics. The company develops extended-release mRNA therapeutics (xRNA) through its proprietary TERÅ platform, which screens xRNA molecules for superior stability and safety. These therapeutics are designed to address unmet medical needs in metabolic, hematologic, infectious disease, and fibrotic disorder areas, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2024, Eleven Therapeutics announced a research and development agreement with Dong-A ST for RNA-based gene therapy, following a partnership with Novo Nordisk in July 2023 to develop nucleic acid therapeutics. These collaborations signal strong industry validation and a strategic focus on expanding its pipeline and therapeutic applications through external partnerships, indicating a robust growth trajectory in the RNA therapeutics space.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent leadership appointment at Eleven Therapeutics?
- In January 2024, Eleven Therapeutics welcomed Dr. Paloma H Giangrande as its Chief Technology Officer, signaling a strengthening of its scientific leadership.
- What strategic partnership did Eleven Therapeutics form in 2023?
- In July 2023, Eleven Therapeutics partnered with Novo Nordisk to develop nucleic acid therapeutics, indicating a significant collaboration with a major pharmaceutical company.
- Which company did Eleven Therapeutics sign an R&D agreement with in early 2024?
- In January 2024, Eleven Therapeutics signed an R&D agreement with Dong-A ST for RNA-based gene therapy, expanding its development efforts in this area.
- When did Eleven Therapeutics raise its seed funding round and how much was it?
- In August 2022, Eleven Therapeutics raised $22M in seed funding from investors.
- When did Eleven Therapeutics secure its pre-seed funding round?
- In September 2020, Eleven Therapeutics secured pre-seed funding, with Entrée Capital as a lead investor.